文献速递慢性肾脏病肾小球疾病遗传性与小管间质肾病

髓系细胞与肾脏的相互作用:健康与疾病

The Myeloid-Kidney Interface in Health and Disease.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-09-10

本文综述了髓系细胞在肾脏稳态中的监视网络作用,及其失调如何导致肾脏结构损伤和纤维化,进而促进CKD进展。还讨论了循环髓系细胞缺陷(如ANCA相关血管炎中的中性粒细胞)、髓系白血病和骨髓增生异常综合征对肾脏的影响,以及克隆性造血这一新认识的癌前临床实体可能带来的肾脏后遗症。现有靶向髓系细胞的疗法包括糖皮质激素受体激动剂和盐皮质激素受体拮抗剂,未来治疗指征有望扩大。

要点

  • 肾脏驻留的促炎和促纤维化巨噬细胞失调可导致肾损伤后结构损伤和瘢痕形成。
  • 克隆性造血是一种常见的新认识癌前临床实体,以高炎症性髓系细胞克隆扩增为特征,可能对肾脏产生显著后遗症。
  • 现有CKD疗法中,糖皮质激素受体激动剂和盐皮质激素受体拮抗剂可靶向髓系细胞和炎症。

核心结论

  • 髓系细胞在肾脏健康中起关键监视作用,其失调参与多种肾脏疾病的发生和进展。

研究设计与样本

  • 本文为综述,检索范围未在摘要中明确报告。

主要发现

  • 肾脏驻留的促炎和促纤维化巨噬细胞失调导致肾损伤后结构损伤和瘢痕形成。
  • 肾实质纤维化促进CKD进展性功能下降,且不依赖于病因。
  • 携带内在缺陷的循环髓系细胞可影响肾脏亚结构,如ANCA相关血管炎中自身抗体激活的中性粒细胞导致GN。
  • 肾脏可受髓系生成障碍影响,包括急性和慢性髓系白血病及骨髓增生异常综合征。
  • 克隆性造血是一种常见的、新认识的癌前临床实体,以高炎症性髓系 lineage 细胞克隆扩增为特征,可能具有显著肾脏后遗症。

临床怎么用

  • 现有CKD治疗中,糖皮质激素受体激动剂和盐皮质激素受体拮抗剂可靶向髓系细胞和炎症。
  • 随着对髓系-肾脏界面理解的深入,这些及其他靶向髓系细胞治疗的治疗指征有望扩大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Kidney homeostasis is highly dependent upon the correct functioning of myeloid cells. These cells form a distributed surveillance network throughout the kidney, where they play an integral role in the response to organ threat. Dysregulation of resident proinflammatory and profibrotic macrophages leads to kidney structural damage and scarring after kidney injury. Fibrosis throughout the kidney parenchyma contributes to the progressive functional decline observed in CKD, independent of the etiology. Circulating myeloid cells bearing intrinsic defects also affect the kidney substructures, such as neutrophils activated by autoantibodies that cause GN in ANCA-associated vasculitis. The kidney can also be affected by disorders of myelopoiesis, including myeloid leukemias (acute and chronic myeloid leukemias) and myelodysplastic syndromes. Clonal hematopoiesis of indeterminate potential is a common, newly recognized premalignant clinical entity characterized by clonal expansion of hyperinflammatory myeloid lineage cells that may have significant kidney sequelae. A number of existing therapies in CKD target myeloid cells and inflammation, including glucocorticoid receptor agonists and mineralocorticoid receptor antagonists. The therapeutic indications for these and other myeloid cell-targeted treatments is poised to expand as our understanding of the myeloid-kidney interface evolves.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Vlasschaert C, Moran SM, Rauh MJ, et al. The Myeloid-Kidney Interface in Health and Disease. Clin J Am Soc Nephrol. 2021. PMID: 34507968. doi:10.2215/CJN.04120321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。